Literature DB >> 8570005

Acetyl-L-carnitine attenuates neuronal damage in gerbils with transient forebrain ischemia only when given before the insult.

A Shuaib1, T Waqaar, T Wishart, R Kanthan, W Howlett.   

Abstract

The underlying mechanisms leading to neuronal damage in cerebral ischemia are multifactoral. In this study, we evaluated the neuroprotective effects of acetyl-L-carnitine, a medication that may enhance metabolic recovery after cerebral ischemia. The 5-minute transient forebrain ischemia model in gerbils was used. Acetyl-L-carnitine was given 30 minutes before the insult in one set of animals and 30 minutes after the insult in a second set of animals with histological evaluation at 7 days (Group A) and 28 days (Group B). Damage assessment was done using a 4-point damage score and Mann-Whitney U test was used for statistical analysis. Compared to the controls, there was significant protection in the cerebral cortex, hippocampus and the striatum in animals treated with the medication before the insult in Group A and Group B. Post-ischemic therapy showed little evidence of neuronal protection in either group. Behavioral tests in the Group B animals showed no significant differences between the treated or the saline controls. Our study shows, that pre-ischemic treatment with acetyl-L-carnitine results in neuronal protection. This may have clinical significance in situations (such as bypass surgery) where treatment could be initiated prior to the insult.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8570005     DOI: 10.1007/bf00995555

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  29 in total

1.  Inhibition of postcardiac arrest brain protein oxidation by acetyl-L-carnitine.

Authors:  Y Liu; R E Rosenthal; P Starke-Reed; G Fiskum
Journal:  Free Radic Biol Med       Date:  1993-12       Impact factor: 7.376

2.  Repetitive transient forebrain ischemia in gerbils: delayed neuronal damage in the substantia nigra reticulata.

Authors:  A Shuaib; S Ijaz; J Kalra; W Code
Journal:  Brain Res       Date:  1992-03-06       Impact factor: 3.252

3.  GABA agonist "muscimol" is neuroprotective in repetitive transient forebrain ischemia in gerbils.

Authors:  A Shuaib; R Mazagri; S Ijaz
Journal:  Exp Neurol       Date:  1993-10       Impact factor: 5.330

4.  Neuroprotective effects of phenyl-t-butyl-nitrone in gerbil global brain ischemia and in cultured rat cerebellar neurons.

Authors:  T L Yue; J L Gu; P G Lysko; H Y Cheng; F C Barone; G Feuerstein
Journal:  Brain Res       Date:  1992-03-06       Impact factor: 3.252

5.  Effect of dichloroacetate on regional energy metabolites and pyruvate dehydrogenase activity during ischemia and reperfusion in gerbil brain.

Authors:  Y Katayama; F A Welsh
Journal:  J Neurochem       Date:  1989-06       Impact factor: 5.372

6.  During repetitive forebrain ischemia, post-ischemic hypothermia protects neurons from damage.

Authors:  A Shuaib; S Ijaz; J Kalra; W Code
Journal:  Can J Neurol Sci       Date:  1992-11       Impact factor: 2.104

7.  Gamma-vinyl GABA prevents hippocampal and substantia nigra reticulata damage in repetitive transient forebrain ischemia.

Authors:  A Shuaib; S Ijaz; S Hasan; J Kalra
Journal:  Brain Res       Date:  1992-09-11       Impact factor: 3.252

8.  Clomethiazole protects the brain in transient forebrain ischemia when used up to 4 h after the insult.

Authors:  A Shuaib; S Ijaz; R Kanthan
Journal:  Neurosci Lett       Date:  1995-09-08       Impact factor: 3.046

9.  Prevention of postischemic canine neurological injury through potentiation of brain energy metabolism by acetyl-L-carnitine.

Authors:  R E Rosenthal; R Williams; Y E Bogaert; P R Getson; G Fiskum
Journal:  Stroke       Date:  1992-09       Impact factor: 7.914

Review 10.  Hypothermia as a potential treatment for cerebral ischemia.

Authors:  J Maher; V Hachinski
Journal:  Cerebrovasc Brain Metab Rev       Date:  1993
View more
  8 in total

Review 1.  Mechanisms of ischemic neuroprotection by acetyl-L-carnitine.

Authors:  Santina A Zanelli; Nina J Solenski; Robert E Rosenthal; Gary Fiskum
Journal:  Ann N Y Acad Sci       Date:  2005-08       Impact factor: 5.691

2.  Acetyl-L-carnitine and oxaloacetate in post-treatment against LTP impairment in a rat ischemia model. An in vitro electrophysiological study.

Authors:  K Kocsis; L Knapp; J Mészáros; Z Kis; T Farkas; L Vécsei; J Toldi
Journal:  J Neural Transm (Vienna)       Date:  2014-11-29       Impact factor: 3.575

3.  Neuroprotection by acetyl-L-carnitine after traumatic injury to the immature rat brain.

Authors:  Susanna Scafidi; Jennifer Racz; Julie Hazelton; Mary C McKenna; Gary Fiskum
Journal:  Dev Neurosci       Date:  2011-01-12       Impact factor: 2.984

4.  Effect of in vivo L-acetylcarnitine administration on ATP-ases enzyme systems of synaptic plasma membranes from rat cerebral cortex.

Authors:  Roberto Federico Villa; Federica Ferrari; Antonella Gorini
Journal:  Neurochem Res       Date:  2011-04-09       Impact factor: 3.996

5.  Action of L-acetylcarnitine on different cerebral mitochondrial populations from cerebral cortex.

Authors:  A Gorini; A D'Angelo; R F Villa
Journal:  Neurochem Res       Date:  1998-12       Impact factor: 3.996

Review 6.  Mitochondrial mechanisms of cell death and neuroprotection in pediatric ischemic and traumatic brain injury.

Authors:  Courtney L Robertson; Susanna Scafidi; Mary C McKenna; Gary Fiskum
Journal:  Exp Neurol       Date:  2009-05-07       Impact factor: 5.330

7.  Neuroprotective effects of pre-treatment with l-carnitine and acetyl-L-carnitine on ischemic injury in vivo and in vitro.

Authors:  Rui Zhang; Hong Zhang; Zhongxia Zhang; Tao Wang; Jingya Niu; Dongsheng Cui; Shunjiang Xu
Journal:  Int J Mol Sci       Date:  2012-02-15       Impact factor: 6.208

Review 8.  Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments.

Authors:  Tesfaye W Tefera; Karin Borges
Journal:  Front Neurosci       Date:  2017-01-10       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.